The 1-year risk of relapse is at least 60% after a sentinel transverse myelitis event; 5 although it appears to decline gradually and be affected by race, 6 the risk nadir is not known. That makes it difficult to weigh risk/benefit balance. Second, clinical relapses in NMOSD can be devastating and recover poorly. 7 The potential negative consequences of failure to prevent one NMOSD attack are substantially greater than those associated with failure to prevent one MS attack. Third, disability in NMOSD is almost entirely attack driven; secondary progressive NMOSD occurs in only about 2% of AQP4-IgG-seropositive patients. 8 Thus, unlike in MS, the treatments we use for relapse prevention in NMOSD actually target the key driver of disability. Fourth, our ability to detect meaningful disease activity in NMOSD is currently limited to diagnosing an attack in evolution. We monitor brain magnetic resonance imaging (MRI) in MS, but although most NMOSD patients gradually accumulate nonspecific and asymptomatic subcortical brain lesions, 9 it is not clear whether the lesions represent disease activity that should be extinguished or prevented. Without biomarkers that allow us to either "take the temperature" of subclinical inter-attack NMOSD inflammatory activity (should that meaningfully exist) or to predict an upcoming attack, we are usually in a position of having to sustain a full defensive therapeutic front against an enemy that poses unquantifiable but nonzero ongoing risk. People with NMOSD have NEDA until they suddenly do not.
We have treatments that reduce attack frequency and preserve neurologic function in NMOSD, including three investigational drugs (eculizumab, inebilizumab, and satralizumab) 10 that showed efficacy in recent randomized controlled trials (RCTs). It seems that patients should be treated until we can clearly demonstrate that the risk of treatment outweighs its benefits. Shosha and Rotstein also found some common ground in considering therapeutic "de-escalation" with prolonged remissions. Given the apparent success of modest chronic treatment regimens in some cohorts, most notably low-dose corticosteroids 7, 11 or low/infrequent rituximab administration guided by serum CD27 (memory B cell) monitoring, 12 a reduction in treatment intensity might represent a compromise. Until we have validated predictive biomarkers of either NMOSD disease activity or therapeutic success, I am reluctant to endorse stopping therapy altogether in NMOSD with AQP4-IgG, but I am willing to consider it in select patients with NMOSD without AQP4-IgG or another antibody, especially if they have had fewer and milder attacks with reasonable recovery and have enjoyed several years of remission. Those predictive biomarkers cannot arrive too soon.
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